2. Academic Validation
  3. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

  • Cancer Cell. 2010 Jun 15;17(6):535-46. doi: 10.1016/j.ccr.2010.04.027.
Raymond J Andersen 1,  Nasrin R Mawji,  Jun Wang,  Gang Wang,  Simon Haile,  Jae-Kyung Myung,  Kate Watt,  Teresa Tam,  Yu Chi Yang,  Carmen A Bañuelos,  David E Williams,  Iain J McEwan,  Yuzhou Wang,  Marianne D Sadar
Affiliations

Affiliation

  • 1 Chemistry and Earth & Ocean Sciences, University of British Columbia, 2036 Main Mall, Vancouver, BC, Canada V6T 1Z1.
PMID: 20541699 DOI: 10.1016/j.ccr.2010.04.027
Abstract

Castration-recurrent prostate Cancer (CRPC) is suspected to depend on Androgen Receptor (AR). The AF-1 region in the amino-terminal domain (NTD) of AR contains most, if not all, of the transcriptional activity. Here we identify EPI-001, a small molecule that blocked transactivation of the NTD and was specific for inhibition of AR without attenuating transcriptional activities of related steroid receptors. EPI-001 interacted with the AF-1 region, inhibited protein-protein interactions with AR, and reduced AR interaction with androgen-response elements on target genes. Importantly, EPI-001 blocked androgen-induced proliferation and caused cytoreduction of CRPC in xenografts dependent on AR for growth and survival without causing toxicity.

Figures
Products